Investors

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Events

06 Aug 2018Q2 Financial results : Week of 6th August 2018
View all

Featured Presentation

18 Jun 2018
ObsEva Investor Presentation - June 2018 PDF
16 May 2018
Q1 Report 2018 PDF
16 Apr 2018
Annual Report 2017 PDF
14 Nov 2017
Q3 Report 2017  PDF
16 Aug 2017
Q2 Report 2017  PDF
18 May 2017
Q1 Report 2017  PDF
21 Apr 2017
Annual Report 2016 PDF

Stock Information

NASDAQ :  OBSV (Common Stock)
$16.62 0.06 (0.36%)
Data as of 20 Jul 2018 4:00 p.m. ET
Data provided by Nasdaq.
Refresh quote

For investor relations, please contact:
IR@obseva.ch